Hadassah

Placental Cells Found to Have Potential to Mitigate Acute Radiation Syndrome

Monday, Oct 24 2011

"In pre-clinical studies," notes Prof. Raphael Gorodetsky, head of the Biotechnology and Radiobiology Laboratory at the Sharrett Institute of Oncology at Hadassah University Medical Center, "we found that placental-derived cells potentially have the ability to increase the survival rate of animals following exposure to lethal doses of total body irradiation."

These placental (PLX) cells, developed by Pluristem Therapeutics Inc., treat life-threatening complications associated with Acute Radiation Syndrome (ARS).

During the studies, animals were injected intravenously with either PLX cells or a placebo, on the day after being exposed to lethal doses of radiation. Nine days following treatment with the PLX cells, the animals' bone marrow and spleen were examined for signs of hematopoietic (blood forming) tissue. On day 23, bone marrow and blood samples were examined in the surviving animals. Overall survival and body weight changes were also monitored. The researchers found in the animals treated with the PLX cells:

  • an up to four-fold increase in the survival rate accompanied by a corresponding weight regain
  • an increase in red-cell count on days 21-23
  • an elevated number of hematopoietic colonies on day 9

Over the next few months, Prof. Gorodetsky and his team will focus on better understanding the PLX cells' mechanism of action as an "off the shelf" post radiation treatment, which could potentially be used in the future for treating ARS patients.

"While our experiments using PLX cells in treating radiation exposure are ongoing and still evolving, these initial data are very encouraging," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "PLX cells as a sole treatment may potentially enhance the survival of lethally irradiated individuals. Moreover, since our previous work indicated that PLX cells can enhance the engraftment of hematopoietic stem cells from cord blood, we can offer a multifaceted approach to reduce and treat the destruction of bone marrow that occurs following exposure to high-dose ionizing radiation. Stockpiled PLX cells can be administered acutely and as a bridging therapy to protect the bone marrow."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, Dec 10 2018

A Nurses Council Celebration in Israel: The Milestone Mission

We were honored to meet so many dynamic Hadassah nurses, some longtime and some new members--all of us excited to be together to celebrate the 100th anniversaries of the Hadassah Medical Organization, the Henrietta Szold Hadasssah-Hebrew University Nursing School and HMO's Department of Ophthalmology. And Israel's 70th

READ MORE ›
alt_text

Wednesday, Dec 5 2018

Prof. Chowers’ Long and Meaningful Hadassah Connections

Sophie Szold, mother of Hadassah founder Henrietta, wept when she saw children with flies in their eyes on their maiden trip to pre-state Israel in 1909. Those children had trachoma, endemic in the Middle East in those days.

READ MORE ›
alt_text

Wednesday, Dec 5 2018

Ending the Violence Against Women: Hadassah Staff Joins Nationwide Protests

On December 4, employees from both Hadassah Hospital Ein Kerem and Hadassah Hospital Mount Scopus rallied to end violence against women. “Together we will banish the darkness and return the light to all women,” read banners held by the participants.

READ MORE ›
alt_text

Tuesday, Dec 4 2018

No Ovaries? Mystery Solved By Hadassah Endocrinologist

A few years ago, a mother brought her teenage daughter to see Prof. David Zangen, Director of Pediatric Endocrinology at the Hadassah Medical Organization.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More